Phase 3 Type 2 Diabetes Trial, Recruiting NCT06716203 Sponsor: BrightGene Bio-Medical Technology Co., Ltd. Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 3 Type 2 Diabetes Trial, Recruiting

NCT06716203
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with type 2 diabetes
  • Your Body Mass Index (BMI) — a measure of body weight relative to height — is 23 or above
  • Your weight has been stable (not changing by more than 5%) for at least 3 months before joining
  • Your HbA1c (a blood test that shows your average blood sugar over the past few months) is between 7.5% and 11.0%
  • Your fasting blood sugar level (measured after not eating) is at or below 15.0 mmol/L

Who may not be able to join:

  • You have been diagnosed with type 1 diabetes or another specific type of diabetes other than type 2
  • You have had a cancer diagnosis in the past 5 years, or have a suspected cancer (with some exceptions for certain skin, cervical, prostate, or thyroid cancers that were fully treated with no return — confirm with trial site)
  • You have ever had chronic or acute pancreatitis (inflammation of the pancreas)
  • You have a history of serious allergies — such as being allergic to 3 or more foods or medicines, or having conditions like asthma, hives, or eczema — or you are allergic to a type of diabetes medication called GLP-1 receptor agonists
  • You have a condition that affects your mental capacity or ability to communicate
  • You have a known or suspected history of alcohol or drug misuse
  • You are currently pregnant or breastfeeding
  • The trial doctor feels there is any other reason that makes it unsuitable for you to take part (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Registry
ClinicalTrials.gov
Start date
2 December 2024
Est. completion
29 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change From Baseline in Hemoglobin A1c (HbA1c)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov